Alnylam Pharmaceuticals, Inc. booked $3.7B in FY2025 revenue, growing 65% year over year — faster than most Healthcare companies we track, at a 8.4% net margin.
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.